<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Genzyme Corporation</title>
	<atom:link href="http://www.stockbloghub.com/tag/genzyme-corporation/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Analyst Retains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/04/09/isis-isis-pharmaceuticals-analyst-retains-neutral-on-shares/70654</link>
		<comments>http://www.stockbloghub.com/2011/04/09/isis-isis-pharmaceuticals-analyst-retains-neutral-on-shares/70654#comments</comments>
		<pubDate>Sat, 09 Apr 2011 19:27:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70654</guid>
		<description><![CDATA[We recently reiterated a Neutral recommendation (Zacks #3 Rank – short-term “Hold” rating) on Isis Pharmaceuticals (ISIS). Isis Pharma is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies, such as antisense. The company discovers new drugs and out-licenses them to partners for license fees, milestone payments and royalties. Isis Pharma has partnership agreements with leading pharmaceuticals companies like Genzyme (GENZ) and GlaxoSmithKline (GSK) among others. Isis Pharma also has a collaboration agreement with biotech company, Alnylam Pharmaceuticals (ALNY). Both companies have joined hands to form Regulus Therapeutics, Inc., a company that is focused on microRNA (mRNA) therapeutics. Isis Pharma focuses its research and development efforts primarily on cardiovascular, metabolic and neurodegenerative diseases and cancer while its partners are involved in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/09/isis-isis-pharmaceuticals-analyst-retains-neutral-on-shares/70654/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACXM) Company News for March 31, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/03/31/acxm-company-news-for-march-31-2011-corporate-summary/70355</link>
		<comments>http://www.stockbloghub.com/2011/03/31/acxm-company-news-for-march-31-2011-corporate-summary/70355#comments</comments>
		<pubDate>Thu, 31 Mar 2011 19:12:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Information Technology Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Acxiom Corporation]]></category>
		<category><![CDATA[ACXM]]></category>
		<category><![CDATA[ALGN]]></category>
		<category><![CDATA[Align Technology Inc]]></category>
		<category><![CDATA[BBY]]></category>
		<category><![CDATA[Best Buy Company Inc]]></category>
		<category><![CDATA[BlackRock Inc.]]></category>
		<category><![CDATA[BLK]]></category>
		<category><![CDATA[BRKR]]></category>
		<category><![CDATA[Bruker Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CONN]]></category>
		<category><![CDATA[Conns Inc.]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GEOI]]></category>
		<category><![CDATA[GeoResources Inc]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70355</guid>
		<description><![CDATA[• According to a report from Bloomberg, Valeant Pharmaceuticals (NYSE:VRX) made a hostile bid to acquire Cephalon (NASDAQ:CEPH) for about $73 a share in cash or about $5.7 billion, after earlier bids were rejected • Standard &#38; Poor’s said the world’s biggest asset manager BlackRock Inc (NYSE:BLK) would replace Genzyme Corp. (NASDAQ:GENZ)  in the S&#38;P 500 index  after Friday’s close • Wells Fargo Securities initiated coverage on exploration company GeoResources Inc. (NASDAQ:GEOI)  with an “Outperform” rating • Chinese internet company Qihoo 360 Technology Company (NYSE:QIHU) made its debut on the New York Stock Exchange with a bang with share prices rising 134.48% to close at $34.00 • Data-services provider Acxiom Corp (NASDAQ:ACXM) announced that its CEO had resigned, effective two days ago, and that its CFO plans to step down • Align Technologies (NASDAQ:ALGN) said it ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/31/acxm-company-news-for-march-31-2011-corporate-summary/70355/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRX) Valeant Pharmaceuticals International&#8217;s Sales Benefit Post Merger</title>
		<link>http://www.stockbloghub.com/2011/03/07/vrx-valeant-pharmaceuticals-internationals-sales-benefit-post-merger/67808</link>
		<comments>http://www.stockbloghub.com/2011/03/07/vrx-valeant-pharmaceuticals-internationals-sales-benefit-post-merger/67808#comments</comments>
		<pubDate>Mon, 07 Mar 2011 18:03:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67808</guid>
		<description><![CDATA[Valeant Pharmaceuticals International‘s (VRX) fourth quarter 2010 earnings of 46 cents per share missed the Zacks Consensus Estimate by a cent and was 45.2% below the year-ago earnings of 84 cents per share. Revenues for the quarter increased 102.7% year over year to $514.6 million, in line with the Zacks Consensus. While fourth quarter earnings were within the company’s guidance range of 44 cents to 48 cents per share, revenues were slightly above the guidance of $500 million. Earnings in 2010 declined 19.3% year over year to $1.97 per share, nevertheless beating the Zacks Consensus Estimate of $1.34. Revenues, which saw an increase of 44.0% to $1.18 billion, beat the Zacks Consensus Estimate of $1.15 billion. The increase in revenues was primarily due to the September 2010 merger of Valeant ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/07/vrx-valeant-pharmaceuticals-internationals-sales-benefit-post-merger/67808/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PLX) Protalix BioTherapeutics Sees FDA Setback for Gaucher Drug</title>
		<link>http://www.stockbloghub.com/2011/03/04/plx-protalix-biotherapeutics-sees-fda-setback-for-gaucher-drug/67728</link>
		<comments>http://www.stockbloghub.com/2011/03/04/plx-protalix-biotherapeutics-sees-fda-setback-for-gaucher-drug/67728#comments</comments>
		<pubDate>Sat, 05 Mar 2011 00:49:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67728</guid>
		<description><![CDATA[Protalix BioTherapeutics, Inc. (PLX) was dealt a huge blow recently with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for the company’s Gaucher disease candidate, taliglucerase alfa. FDA Requests Additional Information The FDA asked the company to provide additional information related to clinical and chemistry, manufacturing and controls (CMC). While the agency did not ask the company to conduct additional studies, it asked Protalix to provide data from the company’s switchover and long-term extension trials. Besides this, the FDA asked the company to submit information on testing specifications and assay validation. Depending on specific requirements, the Gaucher disease candidate&#8217;s approval could get delayed by a year. The first-round approval of taliglucerase alfa would have been a major boost for Protalix, which has a strong marketing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/04/plx-protalix-biotherapeutics-sees-fda-setback-for-gaucher-drug/67728/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharmaceutical Industry Outlook &#8211; March 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917</link>
		<comments>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917#comments</comments>
		<pubDate>Thu, 03 Mar 2011 01:14:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67917</guid>
		<description><![CDATA[The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition, including Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. These products generated more than $15 billion in sales in 2010. The effect of the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AA) Stock Market News for February 22, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/02/22/aa-stock-market-news-for-february-22-2011-market-news/67346</link>
		<comments>http://www.stockbloghub.com/2011/02/22/aa-stock-market-news-for-february-22-2011-market-news/67346#comments</comments>
		<pubDate>Tue, 22 Feb 2011 22:11:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Aluminum]]></category>
		<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[AA]]></category>
		<category><![CDATA[Alcoa Inc.]]></category>
		<category><![CDATA[American Public Education Inc]]></category>
		<category><![CDATA[APEI]]></category>
		<category><![CDATA[Aruba Networks Inc.]]></category>
		<category><![CDATA[ARUN]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[Family Dollar Stores Inc.]]></category>
		<category><![CDATA[FDO]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[HealthSpring Inc]]></category>
		<category><![CDATA[HS]]></category>
		<category><![CDATA[INTU]]></category>
		<category><![CDATA[Intuit Inc.]]></category>
		<category><![CDATA[MUR]]></category>
		<category><![CDATA[Murphy Oil Corporation]]></category>
		<category><![CDATA[Rosetta Stone Inc]]></category>
		<category><![CDATA[RST]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67346</guid>
		<description><![CDATA[The markets registered their third straight week of gains as the indices closed with multi-year highs on Friday. China’s measures to curb inflation and continuing tension in the Middle East failed to cause any damage to the markets as energy stocks led the indices higher. On Friday, markets closed after a third straight week of gains. The Dow ended the week 1% higher at 12,391.25, its highest close since June 5, 2008. The index was up 0.6% for the day. The S&#38;P 500 added 0.19% and closed at 1,343.01, its highest closing since June 17, 2008. For the week the index was up 1%. The Nasdaq recorded a marginal rise of 0.08% and ended the day at 2833.95, which is its highest point since October 31, 2007. On a weekly ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/22/aa-stock-market-news-for-february-22-2011-market-news/67346/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Corporation Results Eclipsed by Sanofi-Aventis Deal</title>
		<link>http://www.stockbloghub.com/2011/02/18/genz-genzyme-corporation-results-eclipsed-by-sanofi-aventis-deal/67086</link>
		<comments>http://www.stockbloghub.com/2011/02/18/genz-genzyme-corporation-results-eclipsed-by-sanofi-aventis-deal/67086#comments</comments>
		<pubDate>Fri, 18 Feb 2011 16:44:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Chicago Rivet & Machine Company]]></category>
		<category><![CDATA[CVR]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67086</guid>
		<description><![CDATA[Genzyme Corporation (GENZ) reported fourth quarter earnings of 71 cents per share (excluding one-time items but including the impact of stock-based compensation expense), a couple of cents below the Zacks Consensus Estimate, but significantly above the year-earlier earnings of 17 cents. Excluding the impact of stock-based compensation expense, fourth quarter earnings came in at 82 cents, well above the year-ago period earnings of 29 cents. Results were in line with the preliminary outlook provided by the company in Jan 2011. Fourth quarter results were driven by the increase in shipments of lead product, Cerezyme, as well as Fabrazyme, contributions from other product lines and cost savings. Fourth quarter revenues increased 23% to $1.15 billion. Although revenues were slightly short of the Zacks Consensus Estimate of $1.16 billion, we were pleased ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/18/genz-genzyme-corporation-results-eclipsed-by-sanofi-aventis-deal/67086/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANF) Stock Market News for February 17, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/02/17/anf-stock-market-news-for-february-17-2011-market-news/67161</link>
		<comments>http://www.stockbloghub.com/2011/02/17/anf-stock-market-news-for-february-17-2011-market-news/67161#comments</comments>
		<pubDate>Thu, 17 Feb 2011 23:07:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Apparel Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abercrombie & Fitch Company]]></category>
		<category><![CDATA[ANF]]></category>
		<category><![CDATA[CMCSA]]></category>
		<category><![CDATA[Comcast Corporation]]></category>
		<category><![CDATA[DE]]></category>
		<category><![CDATA[Deere & Company]]></category>
		<category><![CDATA[Family Dollar Stores Inc.]]></category>
		<category><![CDATA[FDO]]></category>
		<category><![CDATA[Frontier Oil Corporation]]></category>
		<category><![CDATA[FTO]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[HOC]]></category>
		<category><![CDATA[Holly Corporation]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Valero Energy Corporation]]></category>
		<category><![CDATA[VLO]]></category>
		<category><![CDATA[Western Refining Inc.]]></category>
		<category><![CDATA[WNR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67161</guid>
		<description><![CDATA[Markets ended in the green after optimistic news about the economy from the Fed lifted the mood of investors. Earlier in the day, news of strong earnings and deals sent the markets higher. The Dow Jones Industrial Average rose 0.5% to 12,228.17. 23 out of 30 stocks of the blue chip index rose with JP Morgan (NYSE:JPM) gaining 2.39% to close at $47.94, making it one of the highest gainers of the Dow. The Standard &#38; Poor&#8217;s 500 Index increased 0.63% to 1,336.32. Energy and natural resources companies were the best performers for the index. The Nasdaq Composite gained 0.76% to close at 2,825.56. On the New York Stock Exchange, breadth of the market was positively biased as for every 1 stock that fell, nearly 3 stocks ended in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/17/anf-stock-market-news-for-february-17-2011-market-news/67161/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi-Aventis Earnings Meet Expectations &#8211; Decrease From Year-Ago</title>
		<link>http://www.stockbloghub.com/2011/02/11/sny-sanofi-aventis-earnings-meet-expectations-decrease-from-year-ago/66751</link>
		<comments>http://www.stockbloghub.com/2011/02/11/sny-sanofi-aventis-earnings-meet-expectations-decrease-from-year-ago/66751#comments</comments>
		<pubDate>Fri, 11 Feb 2011 15:41:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Chicago Rivet & Machine Company]]></category>
		<category><![CDATA[CVR]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=66751</guid>
		<description><![CDATA[Sanofi-Aventis (SNY) reported fourth quarter earnings of 96 cents per American Depository Share (ADS), a penny above the Zacks Consensus Estimate but below the year-ago earnings of $1.04. Full year earnings came in at $4.69 per ADS, in line with the Zacks Consensus Estimate and 1.7% above the year-ago earnings. Fourth quarter net sales declined 5.9%, with performance being impacted by the genericization of several products, especially Lovenox in the US, US healthcare reform and EU pricing austerity. Full year sales declined 0.8%. During 2010, sales worth more than €2 billion were impacted by generic competition. Meanwhile, EU austerity measures and the US healthcare reform impacted 2010 sales by €450 million. The Quarter in Detail Pharmaceutical segment sales declined 2.7% mainly due to the entry of generic Lovenox and Ambien ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/11/sny-sanofi-aventis-earnings-meet-expectations-decrease-from-year-ago/66751/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer and Protalix BioTherapeutics Seek EU Approval</title>
		<link>http://www.stockbloghub.com/2010/12/21/pfe-pfizer-and-protalix-biotherapeutics-seek-eu-approval/60746</link>
		<comments>http://www.stockbloghub.com/2010/12/21/pfe-pfizer-and-protalix-biotherapeutics-seek-eu-approval/60746#comments</comments>
		<pubDate>Tue, 21 Dec 2010 21:25:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=60746</guid>
		<description><![CDATA[Pfizer (PFE) and its partner Protalix BioTherapeutics Inc. (PLX) recently announced that they have submitted the Marketing Authorization Application (MAA) for their Gaucher disease candidate in the EU. The companies are seeking marketing approval for Uplyso (taliglucerase alfa) from the European Medicines Agency. Uplyso is currently under regulatory review in the US with a response from the Food and Drug Administration (FDA) expected by Feb 25, 2011. Uplyso enjoys orphan drug status in both the EU and the US for the Gaucher disease indication. The approval of Uplyso will be a major boost for Protalix which has a strong marketing partner in Pfizer. The companies entered into a commercialization agreement in late 2009. Per the terms of the agreement, Pfizer has exclusive worldwide rights for the commercialization of Uplyso in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/21/pfe-pfizer-and-protalix-biotherapeutics-seek-eu-approval/60746/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Corporation is in Deal for Sale of Diagnostic Business</title>
		<link>http://www.stockbloghub.com/2010/12/06/genz-genzyme-corporation-is-in-deal-for-sale-of-diagnostic-business/60048</link>
		<comments>http://www.stockbloghub.com/2010/12/06/genz-genzyme-corporation-is-in-deal-for-sale-of-diagnostic-business/60048#comments</comments>
		<pubDate>Tue, 07 Dec 2010 01:24:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=60048</guid>
		<description><![CDATA[Genzyme Corporation (GENZ) recently announced that it has entered into an agreement with Japanese company, Sekisui Chemical Co., Ltd. for the sale of its diagnostic products business. Sekisui will acquire Genzyme’s diagnostic products business for $265 million cash. The diagnostics business delivered $167 million in revenues in 2009. The deal is scheduled to close by year-end. Sale Will Help Genzyme Focus on Core Business Genzyme had initially announced its intention to divest its genetic testing, diagnostic products and pharmaceutical intermediates businesses in May. In Sep, Genzyme entered into an agreement with Laboratory Corporation of America Holdings (LH) for the sale of its genetic testing business for $925 million. Meanwhile, Genzyme’s plan to divest its pharmaceutical intermediates business by year end remains on track. The company could utilize the proceeds from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/06/genz-genzyme-corporation-is-in-deal-for-sale-of-diagnostic-business/60048/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Reports Loss Widens</title>
		<link>http://www.stockbloghub.com/2010/11/15/isis-isis-pharmaceuticals-reports-loss-widens/59429</link>
		<comments>http://www.stockbloghub.com/2010/11/15/isis-isis-pharmaceuticals-reports-loss-widens/59429#comments</comments>
		<pubDate>Tue, 16 Nov 2010 04:57:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59429</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 13 cents per share in the third quarter 2010, wider than the year-ago loss of 12 cents. The higher loss was mainly due to higher operating expenses. However, third quarter loss was narrower than the Zacks Consensus Estimate of a net loss of 20 cents. Following the adoption of a new required accounting standard, Isis is no longer including Regulus Therapeutics&#8217; financial results. Quarter in Detail Third quarter revenues, which include license fees, milestone-related payments and other payments Incorporatedreased 6.9% to $28.6 million. Reported revenues exceeded the Zacks Consensus Estimate of $26 million. Revenues consist of the amortization of milestone and upfront payments received from partners like GlaxoSmithKline (GSK) and Bristol-Myers Squibb (BMY), among others. We note that the company finished ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/isis-isis-pharmaceuticals-reports-loss-widens/59429/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Industry Outlook &#8211; November 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687</link>
		<comments>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687#comments</comments>
		<pubDate>Mon, 15 Nov 2010 18:56:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58687</guid>
		<description><![CDATA[With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. According to IMS Health, these products generated more than $17 billion ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi-Aventis Presents Encouraging Data on MS Drug</title>
		<link>http://www.stockbloghub.com/2010/10/18/sny-sanofi-aventis-presents-encouraging-data-on-ms-drug/55600</link>
		<comments>http://www.stockbloghub.com/2010/10/18/sny-sanofi-aventis-presents-encouraging-data-on-ms-drug/55600#comments</comments>
		<pubDate>Tue, 19 Oct 2010 05:05:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55600</guid>
		<description><![CDATA[French pharmaceutical company, Sanofi-Aventis (SNY) recently presented encouraging results on its multiple sclerosis (MS) candidate, teriflunomide. Results from a phase III randomized, double-blind, placebo-controlled study (TEMSO) showed that teriflunomide helped reduce annualized relapse rates by 31% compared to placebo. The study evaluated two doses of teriflunomide – 7 mg and 14 mg. Sanofi said that treatment with teriflunomide helped reduce the risk of disability progression by 30% and 24% for the 14 mg and 7 mg doses, respectively. The candidate was found to be well-tolerated. Sanofi also presented long-term safety data on relapsing multiple sclerosis patients. Eight years follow-up data from a phase II study showed that the candidate was well-tolerated. The successful development of teriflunomide could provide multiple sclerosis patients with a new first-line treatment option. Teriflunomide is currently ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/18/sny-sanofi-aventis-presents-encouraging-data-on-ms-drug/55600/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi-Aventis Makes Hostile Bid for Genzyme</title>
		<link>http://www.stockbloghub.com/2010/10/11/sny-sanofi-aventis-makes-hostile-bid-for-genzyme/54301</link>
		<comments>http://www.stockbloghub.com/2010/10/11/sny-sanofi-aventis-makes-hostile-bid-for-genzyme/54301#comments</comments>
		<pubDate>Mon, 11 Oct 2010 15:29:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=54301</guid>
		<description><![CDATA[French pharma giant Sanofi-Aventis (SNY) recently went hostile with its bid to acquire biotech company Genzyme Corporation (GENZ). Sanofi has launched a tender offer for all outstanding shares of Genzyme – the offer is scheduled to expire on Dec 10. Sanofi’s offer price stands at $69 per share with the entire deal being valued at $18.5 billion. The $69 offer price represents a 38% premium over Genzyme’s share price on July 1, 2010. Rumors regarding Sanofi’s intention to acquire Genzyme have been doing the rounds since early July 2010. Since then, Genzyme’s shares have shot up more than 40%. Sanofi said that it launched the hostile bid mainly due to Genzyme management’s refusal to enter into constructive discussions with Sanofi. Sanofi had initially approached Genzyme with its $69 per share ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/11/sny-sanofi-aventis-makes-hostile-bid-for-genzyme/54301/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Analyst Cuts Shares to Underperform</title>
		<link>http://www.stockbloghub.com/2010/10/07/ctic-cell-therapeutics-analyst-cuts-shares-to-underperform/54305</link>
		<comments>http://www.stockbloghub.com/2010/10/07/ctic-cell-therapeutics-analyst-cuts-shares-to-underperform/54305#comments</comments>
		<pubDate>Thu, 07 Oct 2010 23:28:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=54305</guid>
		<description><![CDATA[We are downgrading Cell Therapeutics, Inc. (CTIC) to Underperform from Neutral with a price target of $0.25 primarily due to the uncertainty surrounding the US approval of its lead candidate, pixantrone. Pixantrone (proposed trade name: Pixuvri), is currently under development for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL) in patients who have not responded to other treatment options. Cell Therapeutics Inc., based in Seattle, Washington, is focused on developing drugs for cancer. The company received a setback in April 2010, when the US Food and Drug Administration (FDA) denied approval to pixantrone and issued a complete response letter (CRL) based on issues related to the study design. The FDA asked Cell Therapeutics to conduct an additional trial to determine the safety and efficacy of pixantrone. In August ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/07/ctic-cell-therapeutics-analyst-cuts-shares-to-underperform/54305/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Rejects Sanofi-Aventis’ Aquisition Offer</title>
		<link>http://www.stockbloghub.com/2010/09/16/genz-genzyme-rejects-sanofi-aventis%e2%80%99-aquisition-offer/49857</link>
		<comments>http://www.stockbloghub.com/2010/09/16/genz-genzyme-rejects-sanofi-aventis%e2%80%99-aquisition-offer/49857#comments</comments>
		<pubDate>Thu, 16 Sep 2010 16:25:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49857</guid>
		<description><![CDATA[Genzyme Corp. (GENZ) recently rejected Sanofi-Aventis’ (SNY) offer to acquire the company for $69 per share. Earlier in the day, Sanofi had announced its non-binding proposal to Genzyme with the all-cash transaction being valued at $18.5 billion. However, Genzyme’s board of directors rejected the offer calling it unrealistic. According to Genzyme, the offer price undervalues the company. The offer price of $69 per share represents a 38% premium over Genzyme’s share price on July 1, 2010. Rumors regarding Sanofi’s intention to acquire Genzyme have been doing the rounds since early July 2010. Since then, Genzyme’s shares have shot up 35.6%. What Does Sanofi Gain? Sanofi has a high exposure to generic risk on many of its leading franchises. The company suffered a blow recently with the entry of a generic ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/16/genz-genzyme-rejects-sanofi-aventis%e2%80%99-aquisition-offer/49857/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAC) Company News for August 31, 2010 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2010/08/31/bac-company-news-for-august-31-2010-corporate-summary/49898</link>
		<comments>http://www.stockbloghub.com/2010/08/31/bac-company-news-for-august-31-2010-corporate-summary/49898#comments</comments>
		<pubDate>Tue, 31 Aug 2010 17:55:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Money Center Banks]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[DE]]></category>
		<category><![CDATA[Deere & Company]]></category>
		<category><![CDATA[DG]]></category>
		<category><![CDATA[Dollar General Corporation]]></category>
		<category><![CDATA[EXC]]></category>
		<category><![CDATA[Exelon Corporation]]></category>
		<category><![CDATA[Gap Inc.]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GPS]]></category>
		<category><![CDATA[Piper Jaffray Companies]]></category>
		<category><![CDATA[PJC]]></category>
		<category><![CDATA[Rio Tinto plc]]></category>
		<category><![CDATA[RTP]]></category>
		<category><![CDATA[Saks Incorporated]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SKS]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[VF Corporation]]></category>
		<category><![CDATA[VFC]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49898</guid>
		<description><![CDATA[• Some private investors are reportedly considering an offer for Saks (NYSE:SKS). The offer values the luxury retailer at $1.7 billion, or $11 per share • Citigroup (NYSE:C) noted Sanofi-Aventis (NYSE:SNY) may bid up to $74-$77 per share for Genzyme (NASDAQ:GENZ) • Deere (NYSE:DE) plans to sell its wind energy unit to Exelon (NYSE:EXC) for $860 million • Wells Fargo (NYSE:WFC) upgraded Gap (NYSE:GPS) to &#8220;outperform&#8221; from &#8220;market perform,&#8221; with a price target range of $20-$22 • Bank of America (NYSE:BAC) upgraded Rio Tinto (NYSE:RTP) shares to &#8220;buy&#8221; from &#8220;neutral&#8221; • Dollar General (NYSE:DG) posted fiscal second quarter earnings of 42 cents, versus expectatiosn of 38 cents, on inline revenues of $3.21 billion. The company said it sees full-year earnings of $1.67 to $1.74 • Piper Jaffray (NYSE:PJC) downgraded VF Corp. (NYSE:VFC) from &#8220;overweight&#8221; to &#8220;neutral,&#8221; dropping ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/31/bac-company-news-for-august-31-2010-corporate-summary/49898/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Plc Earns European Approval for Vpriv</title>
		<link>http://www.stockbloghub.com/2010/08/28/shpgy-shire-plc-earns-european-approval-for-vpriv/49588</link>
		<comments>http://www.stockbloghub.com/2010/08/28/shpgy-shire-plc-earns-european-approval-for-vpriv/49588#comments</comments>
		<pubDate>Sun, 29 Aug 2010 03:33:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49588</guid>
		<description><![CDATA[Recently, Shire Plc. (SHPGY) received a boost when the European Commission approved its Gaucher disease product Vpriv (velaglucerase alfa) for marketing in 30 European countries. The decision to approve the product does not come as a surprise as the drug’s approval for the long-term treatment of type I Gaucher disease was recommended by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in June 2010. Vpriv, an enzyme replacement therapy, enjoys orphan drug status from the Committee for Orphan Medical Products. Vpriv is already available in the US where it received approval from the US Food and Drug Administration in March 2010. Gaucher disease, a genetically transmitted disease, has an incidence of approximately 1 in a population of 50,000. The disorder mainly leads to the enlargement ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/28/shpgy-shire-plc-earns-european-approval-for-vpriv/49588/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HPQ) Can $1.84 Trillion in Corporate Cash Save U.S. Economy?</title>
		<link>http://www.stockbloghub.com/2010/08/25/hpq-can-1-84-trillion-in-corporate-cash-save-u-s-economy/49288</link>
		<comments>http://www.stockbloghub.com/2010/08/25/hpq-can-1-84-trillion-in-corporate-cash-save-u-s-economy/49288#comments</comments>
		<pubDate>Wed, 25 Aug 2010 17:07:30 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Diversified Computer Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[3PAR]]></category>
		<category><![CDATA[BHP]]></category>
		<category><![CDATA[Bhp Billiton Limited]]></category>
		<category><![CDATA[Bluelinx Holdings Inc]]></category>
		<category><![CDATA[BXC]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[DELL]]></category>
		<category><![CDATA[Dell Inc.]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hewlett-Packard Company]]></category>
		<category><![CDATA[HPQ]]></category>
		<category><![CDATA[PAR]]></category>
		<category><![CDATA[POT]]></category>
		<category><![CDATA[Potash Corporation of Saskatchewan Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49288</guid>
		<description><![CDATA[by Marc Lichtenfeld, Advisory Panelist Wednesday, August 25, 2010: Issue #1331 Scan the headlines these days and a lengthy list of negatives will stare you in the face. Stubbornly high numbers of unemployed Americans. The gargantuan (and ever-increasing) budget deficit. And just yesterday, news that existing home sales recorded a bone-jarring 27% plunge in July, twice as much as forecast. Things are just plain awful, aren’t they? Well, not everything. Despite the many negatives, there are some positives (just don’t hold your breath for the media to tell you about them.) For example, non-financial S&#38;P 500 companies have $837 billion in cash on their balance sheets. That’s a record and is up 26% from a year ago. (My colleague Louis Basenese recently quoted a figure from Moody’s, which claims non-financial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/25/hpq-can-1-84-trillion-in-corporate-cash-save-u-s-economy/49288/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Analyst Maintains Neutral Rating With $58 Target Price</title>
		<link>http://www.stockbloghub.com/2010/08/22/celg-celgene-analyst-maintains-neutral-rating-with-58-target-price/48443</link>
		<comments>http://www.stockbloghub.com/2010/08/22/celg-celgene-analyst-maintains-neutral-rating-with-58-target-price/48443#comments</comments>
		<pubDate>Sun, 22 Aug 2010 23:16:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[SuperGen Inc]]></category>
		<category><![CDATA[SUPG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48443</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $58. Celgene, founded in 1986 and headquartered in Summit, NJ, focuses on the discovery, development and commercialization of drugs in the areas of cancer and immune/inflammatory diseases. The company’s key growth engine is Revlimid, currently approved for myelodysplastic syndrome (MDS) and second-line multiple myeloma (MM). The company is expanding its label into other indications. The drug, which is approved in approximately 50 countries for treating patients suffering from MM who have received at least one prior therapy in combination with dexamethasone, recently received marketing approval in Japan for the same indication. Another important growth driver at Celgene is Vidaza, which is approved for the treatment of MDS. The third marketed product at Celgene is Thalomid, approved ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/22/celg-celgene-analyst-maintains-neutral-rating-with-58-target-price/48443/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Analyst Maintains Neutral Recommendation</title>
		<link>http://www.stockbloghub.com/2010/08/18/celg-celgene-analyst-maintains-neutral-recommendation/48249</link>
		<comments>http://www.stockbloghub.com/2010/08/18/celg-celgene-analyst-maintains-neutral-recommendation/48249#comments</comments>
		<pubDate>Wed, 18 Aug 2010 14:01:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[SuperGen Inc]]></category>
		<category><![CDATA[SUPG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48249</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $58. Celgene, founded in 1986 and headquartered in Summit, NJ, focuses on the discovery, development and commercialization of drugs in the areas of cancer and immune/inflammatory diseases. The company’s key growth engine is Revlimid, currently approved for myelodysplastic syndrome (MDS) and second-line multiple myeloma (MM). The company is expanding its label into other indications. The drug, which is approved in approximately 50 countries for treating patients suffering from MM who have received at least one prior therapy in combination with dexamethasone, recently received marketing approval in Japan for the same indication. Another important growth driver at Celgene is Vidaza, which is approved for the treatment of MDS. The third marketed product at Celgene is Thalomid, approved ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/18/celg-celgene-analyst-maintains-neutral-recommendation/48249/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire plc Second Quarter 2010 Earnings Beat &#8211; Updates Outlook</title>
		<link>http://www.stockbloghub.com/2010/08/10/shpgy-shire-plc-second-quarter-2010-earnings-beat-updates-outlook/47434</link>
		<comments>http://www.stockbloghub.com/2010/08/10/shpgy-shire-plc-second-quarter-2010-earnings-beat-updates-outlook/47434#comments</comments>
		<pubDate>Wed, 11 Aug 2010 01:34:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47434</guid>
		<description><![CDATA[Shire plc (SHPGY) posted earnings of $1.03 per American Depositary Share (ADS) during the second quarter of 2010, beating the Zacks Consensus Estimate of 88 cents and the year-ago earnings of 60 cents per ADS. Improved revenues accounted for the increased earnings. Revenues Quarterly revenues increased 35% year over year to $849 million, well above the Zacks Consensus Estimate of $807.5 million. Increased product sales and higher royalties helped boost revenues. Product sales went up 37% to $764 million, while royalties increased 24% to $85 million. Royalty revenue mainly comprises income earned on the sale of the authorized generic version of Adderall XR. Product sales include sales of Vyvanse (up 30% to $148 million), Elaprase (up 17% to $100 million), Replagal (up 84% to $82 million), Lialda (up 27% to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/10/shpgy-shire-plc-second-quarter-2010-earnings-beat-updates-outlook/47434/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Second Quarter 2010 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2010/08/02/hsp-hospira-second-quarter-2010-earnings-preview/44895</link>
		<comments>http://www.stockbloghub.com/2010/08/02/hsp-hospira-second-quarter-2010-earnings-preview/44895#comments</comments>
		<pubDate>Mon, 02 Aug 2010 21:52:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corporation]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MAXIMUS Inc.]]></category>
		<category><![CDATA[MMS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44895</guid>
		<description><![CDATA[Hospira Inc. (HSP) is scheduled to report its second quarter 2010 results on Wednesday, July 28, before the opening bell. The Zacks Consensus Estimate for the quarter is earnings of 79 cents per share (with an upside of 2.53%), compared with earnings of 73 cents per share in the year-earlier period. The Zacks Consensus Estimate for second-quarter revenue is $1,006 million as against $957 million reported in the year-ago quarter. First-Quarter Recap Hospira Inc.’s first-quarter fiscal 2010 earnings (excluding special items) of 94 cents per share handsomely beat the Zacks Consensus Estimate of 72 cents and the year-ago earnings of 60 cents. On a reported basis, the company earned 84 cents per share, down 18.4% from the year-ago earnings. Revenues for the quarter climbed 17.2% year over year to $1 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/02/hsp-hospira-second-quarter-2010-earnings-preview/44895/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Pharma Merger Mania is Heating Up</title>
		<link>http://www.stockbloghub.com/2010/07/31/mrk-pharma-merger-mania-is-heating-up/45477</link>
		<comments>http://www.stockbloghub.com/2010/07/31/mrk-pharma-merger-mania-is-heating-up/45477#comments</comments>
		<pubDate>Sat, 31 Jul 2010 16:17:01 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45477</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, July 28, 2010: Issue #1311 In the cellphone world, it’s all about “apps.” In the oil and natural gas industries, it’s all about supplies. And in the healthcare sector, it’s all about pills. Lots and lots of pills. Blue pills, purple pills, sleeping pills, anti-depressants. They’re everywhere. It’s big business for Big Pharma and the companies are very good at marketing their products. Comedian Chris Rock referred to this trend, noting that drug companies keep naming symptoms until they find one that you have: Are you sad, are you lonely, are you hot, are you cold? You gotta take this pill! And they don’t even tell you what the pill does… they just keep naming symptoms. I saw a commercial the other day that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/31/mrk-pharma-merger-mania-is-heating-up/45477/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Big Pharma Has a Big Problem and Merger Mania is Heating Up</title>
		<link>http://www.stockbloghub.com/2010/07/28/mrk-big-pharma-has-a-big-problem-and-merger-mania-is-heating-up/45107</link>
		<comments>http://www.stockbloghub.com/2010/07/28/mrk-big-pharma-has-a-big-problem-and-merger-mania-is-heating-up/45107#comments</comments>
		<pubDate>Wed, 28 Jul 2010 18:53:53 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45107</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, July 28, 2010: Issue #1311 In the cellphone world, it’s all about “apps.” In the oil and natural gas industries, it’s all about supplies. And in the healthcare sector, it’s all about pills. Lots and lots of pills. Blue pills, purple pills, sleeping pills, anti-depressants. They’re everywhere. It’s big business for Big Pharma and the companies are very good at marketing their products. Comedian Chris Rock referred to this trend, noting that drug companies keep naming symptoms until they find one that you have: Are you sad, are you lonely, are you hot, are you cold? You gotta take this pill! And they don’t even tell you what the pill does… they just keep naming symptoms. I saw a commercial the other day that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/28/mrk-big-pharma-has-a-big-problem-and-merger-mania-is-heating-up/45107/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204</link>
		<comments>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204#comments</comments>
		<pubDate>Mon, 26 Jul 2010 14:58:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44204</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Second Quarter 2010 Earnings Miss by a Wide Margin</title>
		<link>http://www.stockbloghub.com/2010/07/21/genz-genzyme-second-quarter-2010-earnings-miss-by-a-wide-margin/44257</link>
		<comments>http://www.stockbloghub.com/2010/07/21/genz-genzyme-second-quarter-2010-earnings-miss-by-a-wide-margin/44257#comments</comments>
		<pubDate>Thu, 22 Jul 2010 02:02:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44257</guid>
		<description><![CDATA[Genzyme Corporation (GENZ) reported second quarter earnings of 6 cents per share (excluding one-time items but including the impact of stock-based compensation expense), well below the Zacks Consensus Estimate of 36 cents and the year-earlier earnings of 64 cents. Excluding the impact of stock-based compensation expense, earnings came in at 18 cents. With the company yet to emerge from manufacturing problems, we were not surprised to see the dismal second quarter results. Second quarter revenues declined 12% to $1.08 billion, mainly due to restricted supplies of Cerezyme and Fabrazyme. Genzyme’s Personalized Genetic Health business was the most adversely affected by the temporary shutdown of the company’s Allston Landing facility in June 2009. The Personalized Genetic Health segment posted sales of $350.5 million, down 40%. Production and supply of two products, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/21/genz-genzyme-second-quarter-2010-earnings-miss-by-a-wide-margin/44257/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146</link>
		<comments>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146#comments</comments>
		<pubDate>Wed, 21 Jul 2010 03:08:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire plc Hears Good News From European Medicines Agency</title>
		<link>http://www.stockbloghub.com/2010/07/11/shpgy-shire-plc-hears-good-news-from-european-medicines-agency/41791</link>
		<comments>http://www.stockbloghub.com/2010/07/11/shpgy-shire-plc-hears-good-news-from-european-medicines-agency/41791#comments</comments>
		<pubDate>Sun, 11 Jul 2010 14:23:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=41791</guid>
		<description><![CDATA[Recently Shire plc (SHPGY) announced that its Gaucher disease product VPRIV (velaglucerase alfa) has received a favorable opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The committee recommended the approval of the enzyme replacement therapy for treating type I Gaucher disease. Furthermore, the drug has been granted accelerated assessment by the EMA in the European Union (EU) and enjoys orphan drug status from the Committee for Orphan Medical Products. Shire should be in a position to launch Vpriv in the EU by year end. Meanwhile, product launch in other countries should commence in 2011. Vpriv is already available in the U.S. where it received approval from the U.S. Food and Drug Administration (FDA) in late February 2010. Vpriv Could Eat into Cerezyme’s Market ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/11/shpgy-shire-plc-hears-good-news-from-european-medicines-agency/41791/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Corporation Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2010/05/24/genz-genzyme-corporation-earnings-scorecard/38218</link>
		<comments>http://www.stockbloghub.com/2010/05/24/genz-genzyme-corporation-earnings-scorecard/38218#comments</comments>
		<pubDate>Tue, 25 May 2010 03:53:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=38218</guid>
		<description><![CDATA[Following the release of first quarter results on April 21, 2010, several analysts covering Genzyme Corporation (GENZ) have lowered their earnings estimates for 2010 and 2011. Genzyme is still suffering from the impact of the temporary shutdown of its Allston Landing manufacturing facility last year and has yet to resume normal supply of the key products that were affected by the shutdown. First Quarter Highlights Genzyme reported first quarter earnings of 24 cents per share, above the Zacks Consensus Estimate of 19 cents but well below the year-ago earnings of 70 cents. With the company facing manufacturing problems from mid-2009, we were not surprised to see first quarter revenues decline 6.5% to $1.07 billion, mainly due to restricted supplies of Cerezyme and Fabrazyme. Agreement of Analysts Following the release of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/24/genz-genzyme-corporation-earnings-scorecard/38218/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Reports Smaller Loss Than Expected</title>
		<link>http://www.stockbloghub.com/2010/05/14/isis-isis-pharmaceuticals-reports-smaller-loss-than-expected/37259</link>
		<comments>http://www.stockbloghub.com/2010/05/14/isis-isis-pharmaceuticals-reports-smaller-loss-than-expected/37259#comments</comments>
		<pubDate>Fri, 14 May 2010 15:55:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37259</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 10 cents per share in the first quarter, well below the Zacks Consensus Estimate of a net loss of 17 cents. However, the reported quarter’s loss was higher than the year-ago period’s net loss of a cent mainly due to lower revenues and higher operating expenses. Following the adoption of a new required accounting standard, Isis is no longer including Regulus Therapeutics&#8217; financial results. Regulus has been established in collaboration with Alnylam Pharmaceuticals (ALNY). First quarter revenues, which include license fees, milestone-related payments and other payments, declined 5.2% to $29.9 million. Despite recognizing a $6 million milestone payment received from Bristol-Myers Squibb (BMY), revenues declined during the reported quarter as the company finished amortizing the revenue associated with the $50 million ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/14/isis-isis-pharmaceuticals-reports-smaller-loss-than-expected/37259/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Corporation &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2010/05/13/genz-genzyme-corporation-bear-of-the-day-2/37078</link>
		<comments>http://www.stockbloghub.com/2010/05/13/genz-genzyme-corporation-bear-of-the-day-2/37078#comments</comments>
		<pubDate>Thu, 13 May 2010 22:46:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37078</guid>
		<description><![CDATA[Genzyme (GENZ) has been under a lot of pressure over the past few quarters following the temporary shutdown of its Allston manufacturing facility due to contamination problems. While we are pleased to see that Genzyme is taking steps to emerge from the impact of the temporary shutdown of the Allston plant, we believe that the company may face additional challenges before it is able to go back to a normal production and supply schedule. Moreover, the FDA is looking to enforce a consent decree on the company which would result in Genzyme incurring additional costs. With the company yet to emerge fully from its manufacturing issues, we are downgrading the stock to Underperform. Although Genzyme could receive some positive news in the form of FDA approval of Lumizyme, we expect ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/13/genz-genzyme-corporation-bear-of-the-day-2/37078/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma &amp; Biotech Stock Review &#8211; April 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472</link>
		<comments>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:10:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MIL]]></category>
		<category><![CDATA[Millipore Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35472</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMRN) BioMarin Pharma Announces Good News</title>
		<link>http://www.stockbloghub.com/2010/04/22/bmrn-biomarin-pharma-announces-good-news/34614</link>
		<comments>http://www.stockbloghub.com/2010/04/22/bmrn-biomarin-pharma-announces-good-news/34614#comments</comments>
		<pubDate>Thu, 22 Apr 2010 20:03:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34614</guid>
		<description><![CDATA[BioMarin Pharma Inc. (BMRN) announced recently that its product Firdapse (Amifampridine phosphate) for treating Lambert Eaton Myasthenic Syndrome (LEMS) is commercially available in the European Union. While the company has launched the product in Germany and the UK subsequent launches in other major European markets are expected by the end of the year. The LEMS drug received marketing approval from the European Commission in Dec 2009. Firdapse is the first drug to hit the European market for treating the rare autoimmune disease. Firdapse enjoys orphan drug status and 10 years of market exclusivity in Europe. The drug has also been granted an orphan drug designation by the US Food and Drug Administration (FDA). The drug has the potential to be used for other indications as well Incorporatedluding multiple sclerosis (MS). ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/22/bmrn-biomarin-pharma-announces-good-news/34614/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme First Quarter Earnings Beat by a Penny</title>
		<link>http://www.stockbloghub.com/2010/04/22/genz-genzyme-first-quarter-earnings-beat-by-a-penny/34621</link>
		<comments>http://www.stockbloghub.com/2010/04/22/genz-genzyme-first-quarter-earnings-beat-by-a-penny/34621#comments</comments>
		<pubDate>Thu, 22 Apr 2010 19:57:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34621</guid>
		<description><![CDATA[Genzyme Corporation (GENZ) reported first quarter earnings of 24 cents per share, above the Zacks Consensus Estimate of 19 cents but well below the year-ago earnings of 70 cents. With the company facing manufacturing problems from mid-2009, we were not surprised to see first quarter revenues decline. They fell 6.5% to $1.07 billion, mainly due to restricted supplies of Cerezyme and Fabrazyme. Genzyme’s Personalized Genetic Health business (previously referred to as the Genetic Diseases business) was the most adversely affected by the temporary shutdown of the company’s Allston Landing facility in June 2009. The Personalized Genetic Health segment posted sales of $392.5 million, down 29%. Production and supply of two products, Cerezyme and Fabrazyme, were mainly affected by the temporary shutdown. While Cerezyme sales declined 39% to $179 million, Fabrazyme ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/22/genz-genzyme-first-quarter-earnings-beat-by-a-penny/34621/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Reports Encouraging Data on Multiple Sclerosis Drug Candidate</title>
		<link>http://www.stockbloghub.com/2010/04/18/genz-genzyme-reports-encouraging-data-on-multiple-sclerosis-drug-candidate/34093</link>
		<comments>http://www.stockbloghub.com/2010/04/18/genz-genzyme-reports-encouraging-data-on-multiple-sclerosis-drug-candidate/34093#comments</comments>
		<pubDate>Mon, 19 Apr 2010 01:10:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34093</guid>
		<description><![CDATA[Genzyme Corp. (GENZ) recently reported encouraging follow-up phase II results on its multiple sclerosis candidate alemtuzumab at the annual meeting of the American Academy of Neurology. Alemtuzumab is currently available for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) under the trade name Campath. The study, which compared alemtuzumab with Merck Serono’s Rebif, was conducted in treatment naïve patients suffering from early, active, relapsing-remitting multiple sclerosis (RRMS). Results showed that about 71% of patients treated with alemtuzumab remained free of the disease even three years after treatment compared to 35% in the Rebif arm. Moreover, about 91% of patients in the alemtuzumab arm (versus 68% in the Rebif arm) were free of sustained accumulation of disability. Genzyme reported that 77% of the patients treated with alemtuzumab remained relapse-free compared to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/18/genz-genzyme-reports-encouraging-data-on-multiple-sclerosis-drug-candidate/34093/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Signs Deal with GlaxoSmithKline</title>
		<link>http://www.stockbloghub.com/2010/04/05/isis-isis-pharmaceuticals-signs-deal-with-glaxosmithkline/32813</link>
		<comments>http://www.stockbloghub.com/2010/04/05/isis-isis-pharmaceuticals-signs-deal-with-glaxosmithkline/32813#comments</comments>
		<pubDate>Tue, 06 Apr 2010 03:57:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32813</guid>
		<description><![CDATA[Isis Pharmaceuticals, Inc. (ISIS) recently inked a major deal with GlaxoSmithKline (GSK) under which Isis ’ antisense drug discovery platform will be used for the development of new treatments for rare and serious diseases Incorporatedluding infectious and ocular diseases. Isis will receive an upfront payment of $35 million under the deal which covers up to six programs. In addition to the upfront payment, the company also stands to receive up to $20 million in milestone payments for each program up to the phase II proof-of-concept (PoC) stage. On completion of PoC studies, Glaxo has the option to license the compounds and take over the development and commercialization of the compounds. If all six programs are successful and commercialized to pre-determined sales targets, Isis could receive almost $1.5 billion in license ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/05/isis-isis-pharmaceuticals-signs-deal-with-glaxosmithkline/32813/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Presents Positive Data on Vpriv</title>
		<link>http://www.stockbloghub.com/2010/03/29/shpgy-shire-presents-positive-data-on-vpriv/32189</link>
		<comments>http://www.stockbloghub.com/2010/03/29/shpgy-shire-presents-positive-data-on-vpriv/32189#comments</comments>
		<pubDate>Mon, 29 Mar 2010 20:09:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32189</guid>
		<description><![CDATA[Shire Plc. (SHPGY) recently presented positive phase III data on its Gaucher disease product, Vpriv. The trial was conducted to study the safety of switching patients from Genzyme’s (GENZ) Cerezyme (imiglucerase) to Vpriv. Results showed that both adult as well as pediatric patients who switched from Cerezyme to Vpriv did not develop IgG antibodies to Vpriv. This included 3 patients who tested positive for anti-Cerezyme antibodies at screening. Moreover, it was found that hemoglobin concentration, platelet counts, and liver and spleen volumes remained stable during the one year study, showing safety and maintenance of efficacy during this period. Shire also presented interim safety data from an ongoing multi-center open-label treatment protocol, which was put in place to provide Vpriv to patients affected by the shortage in supply of Cerezyme. Meanwhile, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/shpgy-shire-presents-positive-data-on-vpriv/32189/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Corporation Sees FDA Consent Decree Likely</title>
		<link>http://www.stockbloghub.com/2010/03/27/genz-genzyme-corporation-sees-fda-consent-decree-likely/31996</link>
		<comments>http://www.stockbloghub.com/2010/03/27/genz-genzyme-corporation-sees-fda-consent-decree-likely/31996#comments</comments>
		<pubDate>Sat, 27 Mar 2010 20:43:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31996</guid>
		<description><![CDATA[Just when Genzyme Corp. (GENZ) was slowly making some progress in addressing its manufacturing issues, the company announced that the US Food and Drug Administration (FDA) intends to take enforcement action related to the company’s manufacturing facility at Allston Landing. The FDA has decided to adopt this course so as to ensure that the products manufactured at the Allston Landing manufacturing facility are made in compliance with good manufacturing practice regulations. It is quite likely that the agency will enforce a consent decree which means that a third party will be appointed to inspect and review the plant’s operations, and confirm compliance with FDA regulations. The consent decree will not only be in force for an extended period, it would also require Genzyme to make payments to the government and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/27/genz-genzyme-corporation-sees-fda-consent-decree-likely/31996/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Likely to See FDA Enforcement Action</title>
		<link>http://www.stockbloghub.com/2010/03/25/genz-genzyme-likely-to-see-fda-enforcement-action/31768</link>
		<comments>http://www.stockbloghub.com/2010/03/25/genz-genzyme-likely-to-see-fda-enforcement-action/31768#comments</comments>
		<pubDate>Thu, 25 Mar 2010 19:53:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31768</guid>
		<description><![CDATA[Just when Genzyme Corp. (GENZ) was slowly making some progress in addressing its manufacturing issues, the company announced that the US Food and Drug Administration (FDA) intends to take enforcement action related to the company’s manufacturing facility at Allston Landing. The FDA has decided to adopt this course so as to ensure that the products manufactured at the Allston Landing manufacturing facility are made in compliance with good manufacturing practice regulations. It is quite likely that the agency will enforce a consent decree which means that a third party will be appointed to inspect and review the plant’s operations, and confirm compliance with FDA regulations. The consent decree will not only be in force for an extended period of time, it would also require Genzyme to make payments to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/25/genz-genzyme-likely-to-see-fda-enforcement-action/31768/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals and Genzyme&#8217;s Phase III Drug Data Published</title>
		<link>http://www.stockbloghub.com/2010/03/17/isis-isis-pharmaceuticals-and-genzymes-phase-iii-drug-data-published/30930</link>
		<comments>http://www.stockbloghub.com/2010/03/17/isis-isis-pharmaceuticals-and-genzymes-phase-iii-drug-data-published/30930#comments</comments>
		<pubDate>Wed, 17 Mar 2010 19:34:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[LDL]]></category>
		<category><![CDATA[Lydall Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30930</guid>
		<description><![CDATA[Isis Pharmaceuticals, Inc. (ISIS) and Genzyme Corp. (GENZ) recently announced the publication of phase III data on mipomersen in The Lancet. The data was published from a study that was conducted in patients with homozygous familial hypercholesterolemia (hoFH). Results, which were presented at the annual American Heart Association meeting in November 2009, showed that mipomersen met its primary endpoint. The candidate achieved a 25% reduction in low-density lipoprotein – cholesterol (LDL-C) in an intent-to-treat analysis. Besides meeting the primary endpoint, the study also met each of its secondary and tertiary endpoints, which included statistically significant reductions in apolipoprotein-B, total cholesterol, non- high-density lipoprotein (HDL) cholesterol, lipoprotein (a) [Lp(a)], very low density lipoprotein-cholesterol (VLDL-C) and triglycerides. Mipomersen is Isis’ lead pipeline candidate. It is an antisense drug that targets apolipoprotein B ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/17/isis-isis-pharmaceuticals-and-genzymes-phase-iii-drug-data-published/30930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OSIR) Osiris Therapeutics Misses Estimates</title>
		<link>http://www.stockbloghub.com/2010/03/03/osir-osiris-therapeutics-misses-estimates/29549</link>
		<comments>http://www.stockbloghub.com/2010/03/03/osir-osiris-therapeutics-misses-estimates/29549#comments</comments>
		<pubDate>Wed, 03 Mar 2010 23:02:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[OSIR]]></category>
		<category><![CDATA[Osiris Therapeutics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29549</guid>
		<description><![CDATA[Osiris Therapeutics (OSIR) reported a net loss of a cent in the fourth quarter of 2009, well below the Zacks Consensus Estimate of a net income of 23 cents per share. However, net loss in the year ago period was higher at 37 cents, mainly due to lower revenues and higher clinical trial expenses. Revenues in the reported quarter increased to $10.8 million compared to $6.2 million for the same period of the prior year. Osiris generates revenues from collaborative agreements, research licenses, and government contracts. For 2009, the company reported a loss of 72 cents, well below the loss of $2.18 reported in 2008. Revenues jumped to $44.5 million, significantly above $10 million reported in 2008. Revenues in the reported quarter included the recognition of $10 million in revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/osir-osiris-therapeutics-misses-estimates/29549/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals&#8217; Loss Widens</title>
		<link>http://www.stockbloghub.com/2010/03/03/isis-isis-pharmaceuticals-loss-widens-2/29550</link>
		<comments>http://www.stockbloghub.com/2010/03/03/isis-isis-pharmaceuticals-loss-widens-2/29550#comments</comments>
		<pubDate>Wed, 03 Mar 2010 21:53:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29550</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 16 cents per share in the fourth quarter, which was wider than the Zacks Consensus Estimate of a net loss of 11 cents. The company had reported a net loss of 8 cents in the year ago period. The wider-than-expected loss was due to higher operating expenses. For the full year, the company reported a net loss of 31 cents, well above the net loss of 10 cents reported in 2008. Once again, higher operating expenses accounted for the wider loss despite an increase in revenues. Fourth quarter revenues increased 8.8% to $32.3 million. Revenues were boosted by a $10 million sublicensing fee earned by the company in December 2009 from OncoGenex Pharmaceuticals, Inc. (OGXI), which entered into a licensing agreement ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/isis-isis-pharmaceuticals-loss-widens-2/29550/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMRN) BioMarin Pharmaceutical&#8217;s Earnings Top Analyst Estimates</title>
		<link>http://www.stockbloghub.com/2010/02/24/bmrn-biomarin-pharmaceuticals-earnings-top-analyst-estimates/28892</link>
		<comments>http://www.stockbloghub.com/2010/02/24/bmrn-biomarin-pharmaceuticals-earnings-top-analyst-estimates/28892#comments</comments>
		<pubDate>Wed, 24 Feb 2010 18:54:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28892</guid>
		<description><![CDATA[BioMarin Pharmaceutical Inc. (BMRN) reported fourth-quarter 2009 earnings of 13 cents per share (excluding special items), beating the Zacks Consensus Estimate of break-even earnings. The company had earned 8 cents (excluding special items) in the year-ago quarter. Quarterly Results Revenue for the reported quarter came in at $87.1 million as against $99.3 million in the comparable quarter last year, down 14%. Total net product revenues increased to $83.9 million from $65.9 million in the fourth quarter of 2008. Royalty and license revenues in the quarter came in at $2.8 million as against $1.8 million in the year-ago quarter. Revenue from collaborative agreements accounted for the remaining total revenue in the reported quarter. Revenue from Naglazyme came in at $44.4 million in the reported quarter as against $36.5 million in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/24/bmrn-biomarin-pharmaceuticals-earnings-top-analyst-estimates/28892/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Falls on Drug Concerns</title>
		<link>http://www.stockbloghub.com/2010/02/11/isis-isis-pharmaceuticals-falls-on-drug-concerns/27807</link>
		<comments>http://www.stockbloghub.com/2010/02/11/isis-isis-pharmaceuticals-falls-on-drug-concerns/27807#comments</comments>
		<pubDate>Thu, 11 Feb 2010 23:50:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27807</guid>
		<description><![CDATA[Shares of Isis Pharmaceuticals Inc. (ISIS) slipped more than 2% despite the company reporting positive results on its lead pipeline candidate, mipomersen. Isis and partner, Genzyme Corp. (GENZ) recently announced positive results from a phase III study. Data showed that patients suffering from heterozygous familial hypercholesterolemia (heFH) experienced a 28% reduction in low density lipoprotein (LDL) or “bad&#8221; cholesterol after 26 weeks of treatment with mipomersen. In contrast, patients receiving placebo experienced a 5% increase in cholesterol levels. Although these results were encouraging and statistically significant, concerns regarding the candidate’s safety profile surfaced with the company reporting elevations in liver transaminases, which is a sign of possible liver damage. While the company stated that the elevations were similar to that observed in earlier studies, we remain concerned that concerns regarding ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/11/isis-isis-pharmaceuticals-falls-on-drug-concerns/27807/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) Pharma &amp; Biotech Stock Review &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385</link>
		<comments>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385#comments</comments>
		<pubDate>Sat, 30 Jan 2010 00:08:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26385</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Corporation Gets FDA Action Date for Lumizyme</title>
		<link>http://www.stockbloghub.com/2010/01/23/genz-genzyme-corporation-gets-fda-action-date-for-lumizyme/25768</link>
		<comments>http://www.stockbloghub.com/2010/01/23/genz-genzyme-corporation-gets-fda-action-date-for-lumizyme/25768#comments</comments>
		<pubDate>Sat, 23 Jan 2010 21:27:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25768</guid>
		<description><![CDATA[Genzyme Corp. (GENZ) recently announced that the US Food and Drug Administration (FDA) has assigned an action date for the company’s Biologics License Application for Lumizyme (alglucosidase alfa) for the treatment of Pompe disease. Genzyme is seeking approval for Lumizyme which has been produced at its 4000 liter-scale manufacturing plant in Geel, Belgium. Earlier, Genzyme had submitted an application seeking approval for Lumizyme manufactured at its 2000 liter bioreactor scale at its Allston Landing manufacturing facility. However, the FDA issued a complete response letter in November 2009 stating it will not grant approval unless the company addresses the manufacturing issues at its Allston plant. Based on subsequent discussions with the agency, Genzyme announced that it would resubmit its application and seek approval for the manufacture of the product at the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/23/genz-genzyme-corporation-gets-fda-action-date-for-lumizyme/25768/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Corporation&#8217;s Outlook Stabilizing</title>
		<link>http://www.stockbloghub.com/2010/01/23/genz-genzyme-corporations-outlook-stabilizing/25807</link>
		<comments>http://www.stockbloghub.com/2010/01/23/genz-genzyme-corporations-outlook-stabilizing/25807#comments</comments>
		<pubDate>Sat, 23 Jan 2010 21:16:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25807</guid>
		<description><![CDATA[Genzyme Corp. (GENZ) reports fourth-quarter results on February 17, with the current Zacks Consensus Estimate at 20 cents per share. Recent revisions to the quarterly estimate have been in both directions, with a very modest upward (positive) bias. Of the 12 estimates for the fourth quarter, three have been raised while two have been lowered in the last 30 days. On balance, the estimate is up from 18 cents per share in the last 30 days. If quarterly results come inline with expectations, as is most likely given its recent track record, fourth-quarter 2009 EPS would be 52.4% below the year-earlier level. The year-over-year drop is due to the lingering effects of operational issues at the company&#8217;s Allston Landing, Massachusetts facility. For the full-year 2009, the current Zacks Consensus Estimate ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/23/genz-genzyme-corporations-outlook-stabilizing/25807/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KERX) Healthcare Stock Watch: Short List of Booming (and Busting) Companies</title>
		<link>http://www.stockbloghub.com/2010/01/20/kerx-healthcare-stock-watch-short-list-of-booming-and-busting-companies/25406</link>
		<comments>http://www.stockbloghub.com/2010/01/20/kerx-healthcare-stock-watch-short-list-of-booming-and-busting-companies/25406#comments</comments>
		<pubDate>Wed, 20 Jan 2010 18:11:08 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[KERX]]></category>
		<category><![CDATA[Keryx Biopharmaceuticals Inc]]></category>
		<category><![CDATA[QCOR]]></category>
		<category><![CDATA[Questcor Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25406</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, January 20, 2010: Issue #1179 On my way out to San Francisco last week, I never thought that I’d compare the biggest healthcare conference of the year to the dating scene. But that’s the overall vibe that I took away from the JP Morgan Healthcare Conference. The investors I spoke with reminded me of jilted lovers – eager to get back on the market, but scared to get hurt again. Rather than checking out the eligible candidates on Match.com, though, healthcare investors spend their time poring over companies’ balance sheets and drug pipelines. And so it was in San Francisco. Everyone wanted to be optimistic, but that optimism was only expressed in private conversations. When I saw the same investors in front of companies’ ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/20/kerx-healthcare-stock-watch-short-list-of-booming-and-busting-companies/25406/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

